Luke Evnin Sells 33,948 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $0.67, for a total transaction of $22,745.16. Following the completion of the transaction, the director owned 1,239,060 shares of the company’s stock, valued at $830,170.20. This trade represents a 2.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total transaction of $43,446.40.
• On Friday, May 8th, Luke Evnin sold 305,741 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.70, for a total transaction of $214,018.70.
• On Thursday, May 7th, Luke Evnin sold 79,086 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $49,824.18.
• On Wednesday, May 6th, Luke Evnin sold 14,635 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.66, for a total transaction of $9,659.10.
• On Tuesday, May 5th, Luke Evnin sold 6,860 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.69, for a total transaction of $4,733.40.
• On Monday, May 4th, Luke Evnin sold 47,963 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.72, for a total transaction of $34,533.36.
• On Friday, May 1st, Luke Evnin sold 58,394 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.73, for a total transaction of $42,627.62.
• On Thursday, April 30th, Luke Evnin sold 168,262 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.72, for a total transaction of $121,148.64.
• On Wednesday, April 29th, Luke Evnin sold 56,559 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.69, for a total transaction of $39,025.71.
• On Tuesday, April 28th, Luke Evnin sold 95,412 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.73, for a total transaction of $69,650.76.

Werewolf Therapeutics Trading Down 7.6%

NASDAQ:HOWL opened at $0.58 on Thursday. Werewolf Therapeutics, Inc. has a 1 year low of $0.50 and a 1 year high of $2.38. The firm has a 50 day moving average of $0.81 and a 200-day moving average of $0.83. The stock has a market capitalization of $28.38 million, a P/E ratio of -0.47 and a beta of 0.41.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. As a group, analysts forecast that Werewolf Therapeutics, Inc. will post -1.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Wall Street Zen lowered shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Monday, April 20th. Two analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Werewolf Therapeutics presently has an average rating of “Hold” and an average price target of $3.75.

Institutional Trading of Werewolf Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of HOWL. Jane Street Group LLC acquired a new stake in shares of Werewolf Therapeutics in the second quarter valued at approximately $409,000. Renaissance Technologies LLC increased its holdings in shares of Werewolf Therapeutics by 48.6% in the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock valued at $429,000 after purchasing an additional 221,766 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of Werewolf Therapeutics in the third quarter valued at approximately $304,000. Vanguard Group Inc. increased its holdings in shares of Werewolf Therapeutics by 8.5% in the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after purchasing an additional 109,796 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Werewolf Therapeutics in the second quarter valued at approximately $113,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.